Modality
Gene Editing
MOA
CAR-T CD19
Target
APOC3
Pathway
Incretin
RSVWet AMD
Development Pipeline
Preclinical
~Jun 2020
→ ~Sep 2021
Phase 1
Dec 2021
→ Jun 2027
Phase 1Current
NCT05162471
57 pts·RSV
2021-12→2027-06·Not yet recruiting
NCT06626064
1,895 pts·RSV
2025-06→TBD·Active
1,952 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-02-261mo agoBTD· RSV
2027-06-221.2y awayInterim· RSV
Trial Timeline
2022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3
P1
Not yet…
P1
Active
Catalysts
BTD
2026-02-26 · 1mo ago
RSV
Interim
2027-06-22 · 1.2y away
RSV
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05162471 | Phase 1 | RSV | Not yet recr... | 57 | OS |
| NCT06626064 | Phase 1 | RSV | Active | 1895 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1944 | Pfizer | NDA/BLA | APOC3 | |
| Doxacapivasertib | Eli Lilly | Phase 3 | APOC3 | |
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| Datoglumide | AbbVie | Approved | CFTR | |
| AZN-6294 | AstraZeneca | Phase 2/3 | APOC3 | |
| Zanutinib | Bristol-Myers Squibb | Phase 2/3 | APOC3 | |
| GIL-2259 | Gilead Sciences | Approved | SMN2 | |
| BII-4342 | Biogen | Phase 2/3 | CGRP | |
| ALN-5628 | Alnylam | Phase 1/2 | APOC3 | |
| INC-1582 | Incyte | Phase 1/2 | APOC3 |